Thomson Reuters decides to stay in healthcare game

Luke Gale | | Health Exec | Precision Medicine
Thomson Reuters has shelved plans to sell its healthcare division due to economic conditions that will prevent the company from receiving what the company believes is a fair value for its profitable business.

The New York City-based company will wait until an economic climate more conducive to a divestiture develops to complete a sale, according to a Dec. 22, 2011 statement.

The unit had revenues of approximately $450 million in 2010; however, Thomson Reuters had been planning on selling its healthcare division since June 2011.

Luke Gale

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Why electrophysiologists needed a champion in Washington

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.

Cardiovascular Business
Reimbursement update: What hospitals need to know about new Medicare payments for cardiac CT

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Cardiovascular Business
Stryker acquires Inari Medical for $4.9B

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.